How to buy, sell and short Moderna shares
Moderna shares are traded around the world. As a result, the US biotech firm is on the radar of many investors in the UK. Read on to learn about buying, selling and shorting Moderna shares using the IG platform.
What's on this page?
How to buy or invest in Moderna shares
There are two ways to buy Moderna shares – via derivatives trading or via share trading (investing).
Derivatives, such as CFDs, allow you to speculate on upward or downward share price movements without ever taking ownership of any physical shares. If you want to own the underlying shares, you can invest via share trading. Moderna does not pay dividends to its shareholders, but investors will benefit from an uplift in the company’s value over time.
Follow these steps to trade or invest in Moderna shares:
Investing in Moderna shares
- Create or log in to your share trading account
- Search for ‘Moderna’ in the search panel
- Choose wheter you want to deal 'at quote' or 'on exchange'
- Enter the number of shares you want to buy
- Buy the shares and monitor your investment
How much would it cost to invest in Moderna?
Moderna is listed on the Nasdaq Global Select Market (NASDAQ), which makes it eligible for commission-free trading with IG. You’ll qualify if you have opened three or more positions on your share trading account in the previous month. If you have opened two or fewer positions on your share trading account over the previous month, a fee of £10 will apply.
|FX conversion fee||US best commission||US standard commission|
If you don’t want to take ownership of Moderna shares, you can speculate on the share price with derivatives in order to:
- Get full exposure with a 20%-25% deposit on almost all of our tier one shares1
- Hedge your positions with CFDs and offset any losses against potential profits
How to sell and short Moderna shares
You can sell physical Moderna shares with us, even if you bought them through another provider – by transferring them to us for free. Or, you can go short on the share price by speculating on downward price movements. The benefits of short-selling include the ability to profit from falling share prices, and the opportunity to hedge against any existing investments or long positions.
Selling Moderna shares
- Create or log in to your share trading account
- Look for ‘Moderna’ in the search panel
- Choose whether you want to deal ‘at quote’ or ‘on exchange’
- Enter the number of shares you want to sell
- Sell the shares and monitor your investment
Moderna’s live market price
Moderna shares are listed on the NASDAQ under the ticker MRNA, where it is a constituent of the Nasdaq 100. It is also listed on the MSCI US Equity Indexes.
Moderna’s stock has performed well since the company floated on the Nasdaq Global Select Market in December 2018, but the stock price soared after the biotech company had its Covid-19 vaccine approved by the FDA in December 2020. Between 21 February 2020 and 19 February 2021, Moderna’s share price increased by an enormous 858.52%.
In its 2020 full year results, the company revealed that it aimed to supply over a billion doses of its Covid-19 vaccine in 2021, generating revenue of approximately $18.4 billion.
What is Moderna’s business model?
Moderna’s business model is based around the use of mRNA technology to accelerate drug discovery and early vaccine development.
It was the first American firm to launch an effective vaccine for Covid-19. Since the Moderna vaccine was approved by the FDA in December 2020, the company has focused on expanding its distribution pipeline in order to meet global demand.
Moderna believes that mRNA could be used to create a new category of medicines. It is currently running discovery programmes into infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
Moderna key personnel: who manages the company?
Moderna has filled its executive committee with an international team of medical professionals and corporate veterans.
The key players are:
|Stéphane Bancel||Chief executive officer|
|Juan Andres||Chief technical operations and quality officer|
|Marcello Damiani||Chief digital and operational excellence officer|
|Tracey Franklin||Chief human resources officer|
|Lori Henderson||General counsel and corporate secretary|
|Ray Jordan||Chief corporate affairs officer|
|Corinne Le Goff||Chief commercial officer|
|David Meline||Chief financial officer|
|Tal Zaks||Chief medical officer|
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get commission from just 0.08% on major global shares
- Trade CFDs straight into order books with direct market access